Marco Essig

Marco Essig

Auto-generated profile, based on publicly available information

Marco Essig

Department of Radiology, University of Manitoba, Winnipeg, Canada

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in American Journal of Roentgenology
Verified
Journal Article
Closed access
MEMarco Essig
Marco Essig
MSMark S. Shiroishi
Mark S. Shiroishi
TNThanh Binh Nguyen
Thanh Binh Nguyen
MSMarc Saake
Marc Saake
JPJames M. Provenzale
James M. Provenzale
MLMeng Law
Meng Law
OBJECTIVE. This and its companion article address the 10 most frequently asked questions that radiologists face when planning, performing, processing, and interpreting different MR perfusion studie...

27 June 2006 in Neurology
Verified
Journal Article
Closed access
PDF file
MWM. A. Weber
M. A. Weber
SZS. Zoubaa
S. Zoubaa
MSM. Schlieter
M. Schlieter
EJE. JütTler
E. JütTler
HHH. B. Huttner
H. B. Huttner
MEM. Essig
M. Essig
Objective: To assess the value of spectroscopic and perfusion MRI for glioma grading and for distinguishing glioblastomas from metastases and from CNS lymphomas. Methods: The authors examined 79 consecutive patients with first detection of a brain neoplasm on nonenhanced CT scans and no therapy prior to evaluation. Spectroscopic MRI; arterial spin-labeling MRI for measuring cerebral blood flow (CBF); first-pass dynamic, susceptibility-weighted, contrast-enhanced MRI for measuring cerebral blood volume; and T1-weighted dynamic contrast-enhanced MRI were performed. Receiver operating characteristic analysis was performed, and optimum thresholds for tumor classification and glioma grading were determined. Results: Perfusion MRI had a higher diagnostic performance than spectroscopic MRI. Because of a significantly higher tumor blood flow in glioblastomas compared with CNS lymphomas, a threshold value of 1.2 for CBF provided sensitivity of 97%, specificity of 80%, positive predictive value (PPV) of 94%, and negative predictive value (NPV) of 89%. Because CBF was significantly higher in peritumoral nonenhancing T2-hyperintense regions of glioblastomas compared with metastases, a threshold value of 0.5 for CBF provided sensitivity, specificity, PPV, and NPV of 100%, 71%, 94%, and 100%. Glioblastomas had the highest tumor blood flow values among all other glioma grades. For discrimination of glioblastomas from grade 3 gliomas, sensitivity was 97%, specificity was 50%, PPV was 84%, and NPV was 86% (CBF threshold value of 1.4), and for discrimination of glioblastomas from grade 2 gliomas, sensitivity was 94%, specificity was 78%, PPV was 94%, and NPV was 78% (CBF threshold value of 1.6). Conclusion: Perfusion MRI is predictive in distinguishing glioblastomas from metastases, CNS lymphomas and other gliomas vs MRI and magnetic resonance spectroscopy.

1 June 2000 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
JDJürgen Debus
Jürgen Debus
DSDaniela Schulz-Ertner
Daniela Schulz-Ertner
LSLothar Schad
Lothar Schad
MEMarco Essig
Marco Essig
BRBernhard Rhein
Bernhard Rhein
MWMichael Wannenmacher
Michael Wannenmacher

11 April 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
PVPeter Vajkoczy
Peter Vajkoczy
PKPjotr Knyazev
Pjotr Knyazev
AKAndrea Kunkel
Andrea Kunkel
HCHans-Holger Capelle
Hans-Holger Capelle
SBSandra Behrndt
Sandra Behrndt
AUAxel Ullrich
Axel Ullrich
Malignant gliomas remain incurable brain tumors because of their diffuse-invasive growth. So far, the genetic and molecular events underlying gliomagenesis are poorly understood. In this study, we have identified the receptor tyrosine kinase Axl as a mediator of glioma growth and invasion. We demonstrate that Axl and its ligand Gas6 are overexpressed in human glioma cell lines and that Axl is activated under baseline conditions. Furthermore, Axl is expressed at high levels in human malignant glioma. Inhibition of Axl signaling by overexpression of a dominant-negative receptor mutant (AXL-DN) suppressed experimental gliomagenesis (growth inhibition >85%, P < 0.05) and resulted in long-term survival of mice after intracerebral glioma cell implantation when compared with Axl wild-type (AXL-WT) transfected tumor cells (survival times: AXL-WT, 10 days; AXL-DN, >72 days). A detailed analysis of the distinct hallmarks of glioma pathology, such as cell proliferation, migration, and invasion and tumor angiogenesis, revealed that inhibition of Axl signaling interfered with cell proliferation (inhibition 30% versus AXL-WT), glioma cell migration (inhibition 90% versus mock and AXL-WT, P < 0.05), and invasion (inhibition 62% and 79% versus mock and AXL-WT, respectively; P < 0.05). This study describes the identification, functional manipulation, in vitro and in vivo validation, and preclinical therapeutic inhibition of a target receptor tyrosine kinase mediating glioma growth and invasion. Our findings implicate Axl in gliomagenesis and validate it as a promising target for the development of approaches toward a therapy of these highly aggressive but, as yet, therapy-refractory, tumors.

1 December 2016 in International Journal of Stroke
Verified
Journal Article
Closed access
SNSimon Nagel
Simon Nagel
DSDevesh Sinha
Devesh Sinha
DDDiana Day
Diana Day
WRWolfgang Reith
Wolfgang Reith
RCRené Chapot
René Chapot
IGIris Quasar Grunwald
Iris Quasar Grunwald
The Alberta Stroke Program Early Computed Tomography Score (ASPECTS) is an established 10-point quantitative topographic computed tomography scan score to assess early ischemic changes. We performed a non-inferiority trial between the e-ASPECTS software and neuroradiologists in scoring ASPECTS on non-contrast enhanced computed tomography images of acute ischemic stroke patients. In this multicenter study, e-ASPECTS and three independent neuroradiologists retrospectively and blindly assessed baseline non-contrast enhanced computed tomography images of 132 patients with acute anterior circulation ischemic stroke. Follow-up scans served as ground truth to determine the definite area of infarction. Sensitivity, specificity, and accuracy for region- and score-based analysis, receiver-operating characteristic curves, Bland-Altman plots and Matthews correlation coefficients relative to the ground truth were calculated and comparisons were made between neuroradiologists and different pre-specified e-ASPECTS operating points. The non-inferiority margin was set to 10% for both sensitivity and specificity on region-based analysis. In total 2640 (132 patients × 20 regions per patient) ASPECTS regions were scored. Mean time from onset to baseline computed tomography was 146 ± 124 min and median NIH Stroke Scale (NIHSS) was 11 (6–17, interquartile range). Median ASPECTS for ground truth on follow-up imaging was 8 (6.5–9, interquartile range). In the region-based analysis, two e-ASPECTS operating points (sensitivity, specificity, and accuracy of 44%, 93%, 87% and 44%, 91%, 85%) were statistically non-inferior to all three neuroradiologists (all p-values <0.003). Both Matthews correlation coefficients for e-ASPECTS were higher (0.36 and 0.34) than those of all neuroradiologists (0.32, 0.31, and 0.3). e-ASPECTS was non-inferior to three neuroradiologists in scoring ASPECTS on non-contrast enhanced computed tomography images of acute stroke patients.

7 March 2004 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DDDeana Demjen
Deana Demjen
SKStefan Klussmann
Stefan Klussmann
SKSusanne Kleber
Susanne Kleber
CZCecilia Zuliani
Cecilia Zuliani
BSBram Stieltjes
Bram Stieltjes
AMAna Martin-Villalba
Ana Martin-Villalba